Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (26531)	11/16/1998 2:49:00 PM
From: Machaon	Read Replies (3) \| Respond to of 32384

I wonder if the AIDS patient on the FDA panel had KS? In the North American Panretin study, 134 patients decided to continue treatment with Panretin Gel after the Clinical Trial ended, resulting in a 49.3% response rate, and 85 patients, who had been taking the placebo, decided to continue their treatment with Panretin Gel resulting in a 29.4% response rate. So..... many AIDS patients with KS lesions wanted to continue treatment, or resume treatment. But, as you said, it was interesting that the one who voted against the gel was an AIDS patient (if the report of this was correct).